Head to Head Analysis: Pluri (NASDAQ:PLUR) and Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Institutional & Insider Ownership

66.0% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by company insiders. Comparatively, 43.2% of Pluri shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Lyell Immunopharma and Pluri”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$40,000.00	9,614.69	-$274.45 million	($12.56)	-1.25
Pluri	$1.02 million	13.54	-$23.82 million	($2.45)	-0.45

Pluri has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Lyell Immunopharma and Pluri, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1	1	6	1	2.78
Pluri	1	0	0	0	1.00

Lyell Immunopharma currently has a consensus price target of $40.86, indicating a potential upside of 161.23%. Given Lyell Immunopharma’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Lyell Immunopharma is more favorable than Pluri.

Volatility & Risk

Lyell Immunopharma has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Pluri has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Profitability

This table compares Lyell Immunopharma and Pluri’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-1,701,066.75%	-107.62%	-80.01%
Pluri	-2,344.59%	N/A	-82.71%

Summary

Pluri beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company developing engineered T-cell therapies for people with cancer, with a focus on solid tumors. Its research aims to improve T cells’ ability to recognize and attack cancer cells and to remain active in the challenging environment inside tumors. The company’s investigational programs have included CAR T-cell and tumor-infiltrating lymphocyte (TIL) therapies. These approaches use a patient’s own immune cells, which are modified or selected and expanded before being administered as a potential treatment.

About Pluri

Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.